Wells Fargo analyst Derek Archila downgraded aTyr Pharma (ATYR) to Equal Weight from Overweight with a $1 price target
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATYR:
- aTyr Pharma downgraded to Neutral from Buy at Lucid Capital
- aTyr Pharma downgraded to Hold from Buy at JonesResearch
- Hold Rating Issued for aTyr Pharma Amid Uncertainty Over Efzofitimod’s Trial Results and Future
- aTyr Pharma downgraded to Neutral from Buy at H.C. Wainwright
- aTyr Pharma downgraded to Market Perform from Outperform at Leerink